Russia ready to discuss alternative resolutions on UN mission to DonbassRussian Politics & Diplomacy September 21, 20:18
UN approves probe into Islamic State crimes in IraqWorld September 21, 20:10
Russia’s Alrosa mined all-time largest pink diamond in its historyBusiness & Economy September 21, 20:07
Russia submits Zvyagintsev’s film Loveless for OscarsSociety & Culture September 21, 19:16
Diplomat confirms Russia ready to support Iraq in fight against ISRussian Politics & Diplomacy September 21, 19:10
Russian, Syrian diplomats discuss cooperation within OPCWRussian Politics & Diplomacy September 21, 19:01
Putin talks to Russian Alisa voice assistant, inspects unmanned vehicle created by YandexScience & Space September 21, 18:33
China made offer to Rosatom on new nuclear power plant siteBusiness & Economy September 21, 18:29
Russia’s position in FIFA has always been strong — officialSport September 21, 18:28
TOKYO, July 5, 2017 /PRNewswire/. Anaeropharma Science, Inc., a company dedicated to the development of novel therapeutics to target hypoxic solid tumors, announced on July 5 it has secured US$13.2 million in new capital. The participants in the financing round include three new investors, Novartis, Shinsei Corporate Investment Limited and Seventure Partners' Health for Life Capital fund, and two existing investors, Innovation Network Corporation of Japan and Mitsubishi UFJ Capital's managed fund. Anaeropharma will use the financing to accelerate the development of multiple programs based on its proprietary platform technology.
Anaeropharma is a biopharmaceutical company engaged in research and development of drug candidates that target hypoxic microenvironments of tumors by using recombinant "Bifidobacterium". This approach offers broad potential to be more effective to solid tumors and less toxic to healthy tissues than conventional anti-cancer drugs. APS001F, a recombinant "Bifidobacterium" to express Cytosine Deaminase which converts a prodrug, 5-FC, to an anti-cancer drug, 5-FU, is its leading development product which is under a clinical trial in the U.S., and additional programs in the immune oncology area such as immune checkpoint blockers and other immune-related molecules expressing recombinant "Bifidobacteria" are under active development.
CONTACT: (Mr.) Tetsuya Mishima, President & CEO, Anaeropharma Science, Inc., Tel: +81-3-5642-8081, Email: email@example.com